These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38273190)

  • 1. Probing the glioma microvasculature: a case series of the comparison between perfusion MRI and intraoperative high-frame-rate ultrafast Doppler ultrasound.
    Alafandi A; Tbalvandany SS; Arzanforoosh F; van Der Voort SR; Incekara F; Verhoef L; Warnert EAH; Kruizinga P; Smits M
    Eur Radiol Exp; 2024 Jan; 8(1):13. PubMed ID: 38273190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
    Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
    Thomsen H; Steffensen E; Larsson EM
    Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
    Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
    Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.
    Sahin N; Melhem ER; Wang S; Krejza J; Poptani H; Chawla S; Verma G
    Neuroradiol J; 2013 Oct; 26(5):531-41. PubMed ID: 24199813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
    Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
    Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
    Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
    Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging.
    Togao O; Hiwatashi A; Yamashita K; Kikuchi K; Keupp J; Yoshimoto K; Kuga D; Yoneyama M; Suzuki SO; Iwaki T; Takahashi M; Iihara K; Honda H
    Eur Radiol; 2017 Feb; 27(2):578-588. PubMed ID: 27003139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
    Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
    Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative Grading of Glioma Using Dynamic Susceptibility Contrast MRI: Relative Cerebral Blood Volume Analysis of Intra-tumoural and Peri-tumoural Tissue.
    Soliman RK; Gamal SA; Essa AA; Othman MH
    Clin Neurol Neurosurg; 2018 Apr; 167():86-92. PubMed ID: 29471287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
    Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
    Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy target volume definition in newly diagnosed high grade glioma using
    Dissaux G; Dissaux B; Kabbaj OE; Gujral DM; Pradier O; Salaün PY; Seizeur R; Bourhis D; Ben Salem D; Querellou S; Schick U
    Radiother Oncol; 2020 Sep; 150():164-171. PubMed ID: 32580001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study.
    Withey SB; MacPherson L; Oates A; Powell S; Novak J; Abernethy L; Pizer B; Grundy R; Morgan PS; Bailey S; Mitra D; Arvanitis TN; Auer DP; Avula S; Peet AC
    Pediatr Radiol; 2022 May; 52(6):1134-1149. PubMed ID: 35290489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas.
    Young R; Babb J; Law M; Pollack E; Johnson G
    J Magn Reson Imaging; 2007 Oct; 26(4):1053-63. PubMed ID: 17896374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
    Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
    Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma.
    Nierobisch N; Ludovichetti R; Kadali K; Fierstra J; Hüllner M; Michels L; Achangwa NR; Alcaide-Leon P; Weller M; Kulcsar Z; Hainc N
    Eur J Radiol; 2023 Oct; 167():111076. PubMed ID: 37666072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.